Patient Death Likely from Virus Used to Deliver Gene-Editing Therapy: NEJM Study

A paper published on Thursday in The New England Journal of Medicine suggests that the potential cause of the 2022 death of a Duchenne muscular dystrophy patient was due to an innate immune reaction triggered by the high dose of recombinant adeno-associated virus used to deliver the gene therapy.